Literature DB >> 6831819

Interaction between digoxin and calcium antagonists and antiarrhythmic drugs.

G G Belz, W Doering, R Munkes, J Matthews.   

Abstract

The influence of several calcium antagonists and antiarrhythmic drugs on digoxin kinetics and actions were investigated in 36 healthy men during digoxin steady state (0.375 mg/day). The subjects were randomly assigned to three subgroups and each group received placebo (control) and two of the following regimens (doses three times a day) in a randomized sequence for 2 wk each: verapamil (80 mg) and nifedipine (10 mg), verapamil (120 mg) and gallopamil (50 mg), or propafenone (150 mg) and quinidine (250 mg). Plasma digoxin concentration (PDC) rose during the cotreatments in the sequence: gallopamil (+16%) less than propafenone (+37%) less than nifedipine (+45%) less than verapamil (almost independent of dose, +69%) less than quinidine (+118%). These increases in PDC correlated closely to decreases in renal digoxin clearances. Renal creatinine clearance was virtually unaffected. The rise of PDC resulted in increased glycoside effects, as measured by the shortening of systolic time intervals and flattening of T wave. There was a linear correlation between PDC and changes in mean corrected electromechanical systole and T wave flattening. We conclude that, in addition to quinidine, other antiarrhythmic drugs and various calcium antagonists interact kinetically with digoxin and that the increasing PDCs are cardioactive.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831819     DOI: 10.1038/clpt.1983.55

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  38 in total

1.  Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK).

Authors:  Mitsuo Saito; Mutsuko Hirata-Koizumi; Shinji Miyake; Ryuichi Hasegawa
Journal:  Eur J Clin Pharmacol       Date:  2005-07-23       Impact factor: 2.953

Review 2.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 3.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 4.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 5.  Drug interactions that matter. A critical reappraisal.

Authors:  G T McInnes; M J Brodie
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

6.  Identification of severe potential drug-drug interactions using an Italian general-practitioner database.

Authors:  L Magro; A Conforti; F Del Zotti; R Leone; M L Iorio; I Meneghelli; D Massignani; E Visonà; U Moretti
Journal:  Eur J Clin Pharmacol       Date:  2007-11-09       Impact factor: 2.953

Review 7.  Calcium antagonists in the elderly. A risk-benefit analysis.

Authors:  J B Schwartz
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

8.  Digoxin-diltiazem interaction: a pharmacokinetic evaluation.

Authors:  W N Jones; K B Kern; J P Rindone; M Mayersohn; M Bliss; S Goldman
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Influence of nisoldipine on haemodynamic effects and plasma levels of digoxin.

Authors:  W Kirch; J Stenzel; P Dylewicz; H J Hutt; S R Santos; E E Ohnhaus
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

10.  Verapamil-induced changes in digoxin kinetics in cirrhosis.

Authors:  I Maragno; C Gianotti; P F Tropeano; V Rodighiero; R M Gaion; C Paleari; R Prandoni; L Menozzi
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.